PM
IOVA icon

Prosight Management’s Iovance Biotherapeutics IOVA Stock Holding History

Prosight Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,000
Closed -$333K – 31
2022
Q1 		$333K Sell
20,000
-48,800
-71% -$755K 0.22% 31
2021
Q4 		$1.31M Sell
68,800
-205,961
-75% -$4.53M 0.79% 28
2021
Q3 		$6.78M Buy
274,761
+135,875
+98% +$3.2M 3.73% 7
2021
Q2 		$3.61M Buy
+138,886
New +$3.61M 2.26% 19
2020
Q4 		– Sell
-120,606
Closed -$3.97M – 48
2020
Q3 		$3.97M Sell
120,606
-94,394
-44% -$2.89M 1.89% 21
2020
Q2 		$5.9M Sell
215,000
-338,100
-61% -$11.1M 2.53% 16
2020
Q1 		$16.6M Buy
553,100
+164,500
+42% +$4.36M 7.74% 2
2019
Q4 		$10.8M Buy
388,600
+42,451
+12% +$966K 4.72% 7
2019
Q3 		$6.3M Sell
346,149
-53,851
-13% -$1.19M 3.49% 10
2019
Q2 		$9.81M Sell
400,000
-517,080
-56% -$7.79M 4.95% 5
2019
Q1 		$8.72M Sell
917,080
-145,420
-14% -$1.41M 3.82% 8
2018
Q4 		$9.4M Buy
1,062,500
+347,183
+49% +$3.35M 4.85% 7
2018
Q3 		$8.05M Buy
715,317
+275,417
+63% +$3.91M 4.49% 8
2018
Q2 		$5.63M Buy
439,900
+230,058
+110% +$3.36M 4.13% 9
2018
Q1 		$3.55M Sell
209,842
-297,010
-59% -$4.5M 2.22% 17
2017
Q4 		$4.05M Buy
+506,852
New +$4.07M 2.98% 14

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Prosight Management's IOVA Position: Q2 2022 in Review

Prosight Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2022, closing a stake of 20,000 shares — an estimated $333K sold.

Prosight Management first reported a position in IOVA in Q4 2017 and held it in 16 quarters. The position peaked at $16.6M in Q1 2020. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

  • Prosight Management reported no remaining Iovance Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Prosight Management sold 20,000 Iovance Biotherapeutics shares in Q2 2022, an estimated $333K.
  • Prosight Management first reported a position in Iovance Biotherapeutics in Q4 2017 and held it in 16 quarters.
  • Prosight Management's Iovance Biotherapeutics position peaked at $16.6M in Q1 2020.
  • 237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on Prosight Management's 13F filing for Q2 2022, filed 12 Aug 2022.